2026_St_6T_Basic_Mapd
Defines step therapy coverage requirements for multiple branded products (Exxua, Fanapt, Auvelity, Raldesy and others) across several drug groups. Specifies which Step 1 and Step 2 agents count toward prerequisite trials, trial duration/measure (>=1-day supply in prior 180 days), exceptions (suicidal ideation, current or prior use), and product lists affected.
No material clinical or coverage changes.
Coverage Summary
Defines step therapy coverage requirements for multiple branded products (Exxua, Fanapt, Auvelity, Raldesy and others). Coverage status: covered with criteria. Step therapy applies to each branded product and their related product groups (e.g., Exxua, Fanapt, Auvelity, Raldesy), with specified Step 1 and Step 2 agents and a trial rule of at least a 1-day supply in the prior 180 days to meet prerequisites. Exceptions that permit approval without required trials include documented suicidal ideation or current/prior use of the requested product.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.